These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 17196362

  • 1. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
    Siegel R, Hauschild A, Kettelhack C, Kähler KC, Bembenek A, Schlag PM.
    Eur J Surg Oncol; 2007 Jun; 33(5):627-32. PubMed ID: 17196362
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
    Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S.
    Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
    [Abstract] [Full Text] [Related]

  • 3. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
    Cui CL, Chi ZH, Yuan XQ, Lian HY, Si L, Guo J.
    Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
    [Abstract] [Full Text] [Related]

  • 4. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
    Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L.
    J Clin Oncol; 1997 Jul; 15(7):2589-95. PubMed ID: 9215829
    [Abstract] [Full Text] [Related]

  • 5. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
    Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB.
    Br J Cancer; 2002 Oct 07; 87(8):840-5. PubMed ID: 12373596
    [Abstract] [Full Text] [Related]

  • 6. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.
    J Clin Oncol; 2004 Mar 15; 22(6):1118-25. PubMed ID: 15020614
    [Abstract] [Full Text] [Related]

  • 7. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.
    van Etten B, de Wilt JH, Brunstein F, Eggermont AM, Verhoef C.
    Eur J Surg Oncol; 2009 May 15; 35(5):539-45. PubMed ID: 18760560
    [Abstract] [Full Text] [Related]

  • 8. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC.
    Clin Cancer Res; 2000 Aug 15; 6(8):3062-70. PubMed ID: 10955785
    [Abstract] [Full Text] [Related]

  • 9. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
    Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.
    Ann Oncol; 2014 Mar 15; 25(3):742-746. PubMed ID: 24510314
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study.
    Farolfi A, Ridolfi L, Guidoboni M, Milandri C, Calzolari F, Scarpi E, Amadori D, Ridolfi R.
    J Chemother; 2011 Oct 15; 23(5):300-5. PubMed ID: 22005064
    [Abstract] [Full Text] [Related]

  • 12. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
    Richtig E, Ludwig R, Kerl H, Smolle J.
    Br J Dermatol; 2005 Nov 15; 153(5):925-31. PubMed ID: 16225601
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP.
    Cancer Invest; 1994 Nov 15; 12(4):414-20. PubMed ID: 8032964
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
    Schuster R, Lindner M, Wacker F, Krössin M, Bechrakis N, Foerster MH, Thiel E, Keilholz U, Schmittel A.
    Melanoma Res; 2010 Jun 15; 20(3):191-6. PubMed ID: 20335820
    [Abstract] [Full Text] [Related]

  • 19. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases.
    Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, D'Angelica M, Fong Y, Jarnagin WR, Allen PJ, Kemeny N.
    Ann Surg Oncol; 2009 Jul 15; 16(7):1844-51. PubMed ID: 19224284
    [Abstract] [Full Text] [Related]

  • 20. [Contribution of a new nitrosourea compound: fotemustine].
    Boaziz C.
    Pathol Biol (Paris); 1992 Dec 15; 40(9 Pt 2):964-8. PubMed ID: 1338920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.